Clinical Scorecard: Treatment Gaps Linked to Worse Long-Term Vision Outcomes in Wet AMD
At a Glance
| Category | Detail |
|---|---|
| Condition | Neovascular Age-Related Macular Degeneration (AMD) |
| Key Mechanisms | Intravitreal anti-VEGF treatment |
| Target Population | Treatment-naïve wet AMD patients |
| Care Setting | Ophthalmology clinics |
Key Highlights
- 40% of patients experienced a treatment gap of at least 180 days by year 1.
- By year 7, 80% of patients had treatment gaps.
- Patients without treatment gaps had better vision outcomes over time.
- Treatment gaps led to less vision improvement and more decline over time.
- Continuous treatment exposure is crucial for optimal vision outcomes.
Guideline-Based Recommendations
Diagnosis
- Monitor for neovascular AMD using appropriate imaging techniques.
Management
- Administer intravitreal anti-VEGF agents consistently without significant gaps.
Monitoring & Follow-up
- Regular follow-up to assess treatment adherence and vision outcomes.
Risks
- Increased risk of vision decline associated with treatment interruptions.
Patient & Prescribing Data
Patients with neovascular AMD requiring anti-VEGF therapy.
Longer duration of action therapies may improve adherence and outcomes.
Clinical Best Practices
- Encourage continuous treatment to avoid significant gaps.
- Educate patients on the importance of regular follow-up appointments.
- Consider emerging therapies with longer action durations.
Related Resources & Content
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.